Public market insider buying at Medicenna Therapeutics (MDNA)

Public market insider buying at Medicenna Therapeutics (T:MDNA)

Fahar Merchant, a Senior Officer, Director and 10% Holder, acquired 39,400 Common Shares on a direct ownership basis at prices ranging from $2.600 to $2.700 on November 5th, 2021. This represents a $105,735 investment into the company's shares and an account share holdings change of 0.7%.

Medicenna Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Medicenna Therapeutics Corp. is an immunotherapy company. The Company is engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) tunable cytokines, called Superkines and Empowered Superkines (ECs). It focuses on commercialization of EC and Superkines for the treatment of cancer and other diseases. The Company's Bi-functional SuperKine ImmunoTherapies (BiSKITs) platform allows to develop designer Superkines by combining them to other proteins, antibodies or naked IL-2, IL-4 and IL-13 Superkines to combine two distinct and synergistic mechanisms of action into one molecule. The Company's product candidates MDNA55, is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a fatal form of brain cancer. MDNA11, an IL-2 Superkine that has been fused with human recombinant albumin. It is being developed as a therapeutic for various solid tumors in combination with other immunotherapies.